Intravitreal silicone oil droplets after intravitreal drug injections

Retina

Volumn 28, Issue 7, 2008, Pages 996-1001

  Bakri, Sophie J ^a   Ekdawi, Noha S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti vascular endothelial growth factor; Bevacizumab (avastin); Droplet; Injection; Intravitreal; Needle; Pegaptanib; Ranibizumab (lucentis); Silicone oil; Syringe; Triamcinolone

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; SILICONE OIL; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR;

ARTICLE; CLINICAL ARTICLE; EYE INFLAMMATION; HUMAN; NEEDLE; SYRINGE; VISUAL ACUITY; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; EYE DISEASES; EYE FOREIGN BODIES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; RETROSPECTIVE STUDIES; SILICONE OILS; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 67749115147     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31816c6868     Document Type: Article

References (18)

1. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113:1508.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
4. Michels S, Prager F, Bakri SJ, Wachtlin J. Bevacizumab for ophthalmic diseases. Expert Review of Ophthalmology 2007; 2:369-378.
5. Ekdawi NS, Bakri SJ. Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone. Eye 2007;21:1128-1130.
6. Mohamed Q, McIntosh RL, Saw SM, et al. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:507-519.
7. Goff MJ, Jumper JM, Yang SS, et al. Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina 2006;26:896-901.
8. Gregori NZ, Rosenfeld PJ, Puliafito CA, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006;26:889-895.
9. Costarides AP, Alabata P, Bergstrom C. Elevated intraocular pressure following vitreoretinal surgery. Ophthalmol Clin North Am 2004;17:507-512.
10. Freund KB, Laud K, Eandi CM, Spaide RF. Silicone oil droplets following intravitreal injection. Retina 2006;26:701-703.
11. Corporation DC. Corning 365, 35% Dimethicone NF Emulsion. Midland, Michigan: Medical Products Division; 2002.
12. Kline D, Kuhn T. Needle reuse and tip damage. Diabetes Care 2004;27:617.
13. Travis WD, Balogh K, Abraham JL. Silicone granulomas: report of three cases and review of the literature. Hum Pathol 1985;16:19-27.
14. Miller JR, Helprin JJ, Finlayson JS. Silicone lubricant flushed from disposable syringes: determination by atomic absorption spectrophotometry. J Pharm Sci 1969;58:455-456.
15. Chantelau E, Berger M, Bohlken B. Silicone oil released from disposable insulin syringes. Diabetes Care 1986;9:672-673.
16. Baldwin RN. Contamination of insulin by silicone oil: a potential hazard of plastic insulin syringes. Diabet Med 1988; 5:789-790.
17. Bernstein RK. Clouding and deactivation of clear (regular) human insulin: association with silicone oil from disposable syringes. Diabetes Care 1987;10:786-787.
18. Suzuki M, Okada T, Takeuchi S, et al. Effect of silicone oil on ocular tissues. Jpn J Ophthalmol 1991;35:282-291.